Drug
Ridinilazole
Ridinilazole is a pharmaceutical drug with 3 clinical trials. Historical success rate of 66.7%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_3
2
67%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (33.3%)
Phase 32 (66.7%)
Trials by Status
completed267%
terminated133%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_3
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
NCT04802837
completedphase_3
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
NCT03595553
completedphase_2
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
NCT02784002
Clinical Trials (3)
Showing 3 of 3 trials
NCT04802837Phase 3
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
NCT03595553Phase 3
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
NCT02784002Phase 2
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3